CHRLS RIVER LABS

 CRLのチャート


 CRLの企業情報

symbol CRL
会社名 Charles River Laboratories International Inc. (CHRLS RIVER LABS)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 チャールズ・リバー・ラボラトリーズ・インターナショナル(Charles River Laboratories International Inc.)は初期段階の創薬と開発プロセスを促進するソリューションを提供する。同社は生体内生物学を中心に事業を展開する。同社のポートフォリオは生体内薬物の発見と開発を支援する研究モデル・サービスを含む。同社は研究モデル・サービス(RMS)区分及び前臨床サービス(PCS)区分の2事業区分を通して運営する。同社はRMS区分を通して、薬剤開発業界向けに研究モデルを提供している。同社は遺伝学的と微生物学的に定義された目的に繁殖されたラット及びマウスを主とする齧歯類の研究モデル系統の生産と販売に従事する。PCS事業区分は依頼人向けに、規制を必要とする安全性評価と関連薬剤開発業務のアウトソーシングサービスを提供する。平成24年8月、同社はAccugenix Incを買収した。平成25年1月、同社はVital Riverの持分の75%を取得した。  チャ―ルズ・リバ―・ラボラトリ―ズ・インタ―ナショナルは、迅速で効率的な新薬創出の実現をサポ―ト。新薬の研究開発から承認までのプロセスに必要な標的探索から臨床試験まで一括提供。事業は研究サ―ビスと前臨床サ―ビスの2部門。サ―ビスは、受託試験、受託飼育、医薬品、化学品、農薬等の受託サ―ビスなど。また、実験動物、研究試薬を生産、販売する。  Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
本社所在地 251 Ballardvale Street Wilmington MA 01887 USA
代表者氏名 James C. Foster
代表者役職名 Chairman of the Board President Chief Executive Officer
電話番号 +1 781-222-6000
設立年月日 1994年
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 14700人
url www.criver.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 519.91300
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 6939.76800
売上高 (百万ドル) 2266.09600
企業価値(EV) (百万ドル) 8411.45500
当期純利益 (百万ドル) 219.36700
決算概要 BRIEF: For the fiscal year ended 29 December 2018 Charles River Laboratories Intl. Inc revenues increased 22% to $2.27B. Net income before extraordinary items increased 9% to $219.4M. Revenues reflect Discovery And Safety Assessment segment increase of 34% to $1.32B Manufacturing Support segment increase of 12% to $429.6M Research Models segment increase of 5% to $519.7M United States segment increase of 32% to $1.27B.

 CRLのテクニカル分析


 CRLのニュース

   Charles River Laboratories Inte – Consensus Indicates Potential 37.3% Upside  2022/05/10 11:00:00 DirectorsTalk
Charles River Laboratories Inte with ticker code (CRL) have now 11 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 378 and 280 calculating the average target price we see 332.18. Now with the previous closing price of 241.96 this would indicate that there is a potential upside of 37.3%. The 50 day MA is 273.61 and the 200 moving average now moves to 357.26. The company has a market capitalisation of $11,627m. You can visit the company''s website by visiting: https://www.criver.com [stock_market_widget type="chart" template="basic" color="green" assets="CRL" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $15,962m based on the market concensus. Charles River Laboratories International, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
   Charles River Laboratories International, Inc. 2022 Q1 - Results - Earnings Call Presentation (NYSE:CRL)  2022/05/06 12:40:29 Seeking Alpha
The following slide deck was published by Charles River Laboratories International, Inc.
   Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q1 2022 Earnings Call Transcript  2022/05/04 18:23:03 Seeking Alpha
Charles River Laboratories International, Inc. (NYSE:NYSE:CRL) Q1 2022 Earnings Conference Call May 04, 2022 09:30 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman,…
   Charles River Laboratories Tops Q1 EPS by 3c By Investing.com  2022/05/04 11:44:01 Investing.com
Charles River Laboratories Tops Q1 EPS by 3c
   Charles River Laboratories Non-GAAP EPS of $2.75 beats by $0.03, revenue of $913.9M beats  2022/05/04 11:05:32 Seeking Alpha
Charles River Laboratories press release (CRL): Q1 Non-GAAP EPS of $2.75 beats by $0.03.Revenue of $913.9M (+10.8% Y/Y) beats by $5.26M.The Company is updating its 2022…
   Charles River CFO David Smith to retire following transition period; sees FY22 EPS of $11.50-$11.75  2022/01/11 12:29:34 Seeking Alpha
Charles River (CRL) announced a retirement and transition plan for its CFO.David R
   Is Charles River Laboratories (CRL) A Worthy Stock Investment?  2021/12/31 12:30:53 Insider Monkey
   Global Knock Out Mouse Model Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com  2021/12/23 16:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Knock out Mouse Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The Knock Out Mouse Model Market Size is projected to register a CAGR of 5.2% during the forecast period. Companies Mentioned Charles River Laboratories International Inc. Cyagen Biosciences. Envigo genOway Ozgene Pty Ltd. Taconic Biosciences, Inc. THE JACKSON LABORATORY TRANS GENIC INC. Key Market Trends Constitut
   Head to Head Contrast: Charles River Laboratories International (NYSE:CRL) & iSpecimen (NASDAQ:ISPC)  2021/12/23 08:42:41 Dakota Financial News
Charles River Laboratories International (NYSE:CRL) and iSpecimen (NASDAQ:ISPC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends. Analyst Recommendations This is a summary of recent ratings and recommmendations for Charles River Laboratories []
   Analysts Expect Charles River Laboratories International, Inc. (NYSE:CRL) Will Post Quarterly Sales of $891.50 Million  2021/12/23 01:14:43 Dakota Financial News
Wall Street brokerages forecast that Charles River Laboratories International, Inc. (NYSE:CRL) will post sales of $891.50 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Charles River Laboratories Internationals earnings, with the lowest sales estimate coming in at $875.12 million and the highest estimate coming in at $921.78 million. []
   Is Charles River Laboratories (CRL) A Worthy Stock Investment?  2021/12/31 12:30:53 Insider Monkey
   Global Knock Out Mouse Model Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com  2021/12/23 16:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Knock out Mouse Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The Knock Out Mouse Model Market Size is projected to register a CAGR of 5.2% during the forecast period. Companies Mentioned Charles River Laboratories International Inc. Cyagen Biosciences. Envigo genOway Ozgene Pty Ltd. Taconic Biosciences, Inc. THE JACKSON LABORATORY TRANS GENIC INC. Key Market Trends Constitut
   Head to Head Contrast: Charles River Laboratories International (NYSE:CRL) & iSpecimen (NASDAQ:ISPC)  2021/12/23 08:42:41 Dakota Financial News
Charles River Laboratories International (NYSE:CRL) and iSpecimen (NASDAQ:ISPC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends. Analyst Recommendations This is a summary of recent ratings and recommmendations for Charles River Laboratories []
   Analysts Expect Charles River Laboratories International, Inc. (NYSE:CRL) Will Post Quarterly Sales of $891.50 Million  2021/12/23 01:14:43 Dakota Financial News
Wall Street brokerages forecast that Charles River Laboratories International, Inc. (NYSE:CRL) will post sales of $891.50 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Charles River Laboratories Internationals earnings, with the lowest sales estimate coming in at $875.12 million and the highest estimate coming in at $921.78 million. []
   Whittier Trust Co. of Nevada Inc. Boosts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)  2021/12/22 11:36:46 Transcript Daily
Whittier Trust Co. of Nevada Inc. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,335 shares of the medical research companys stock after purchasing an additional 235 shares during []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 CHRLS RIVER LABS CRL )

 twitter  (公式ツイッターやCEOツイッターなど)